Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
20 July 2020 | Story Leonie Bolleurs | Photo Supplied
The view from one of the offices in the Marion Island research station, with fresh snowfall in the interior of the island in the background.

Liezel Rudolph, lecturer and researcher in the Department of Geography at the University of the Free State (UFS), is strongly convinced that the Southern Hemisphere’s past glacial cycles will provide valuable insights to help predict and prepare for future climate change. Climate is changing fast and the magnitude of change we have seen over the last 30 years has taken a hundred or several hundred years to occur in the past. 

It is not only temperatures that are rising, but changes in wind patterns, rain cycles, oceanic circulation, etc., are also observed. As we do not know how the earth will respond or adapt to such rapid and drastic changes in climatic patterns, this poses various threats.

Link between landscape responses and climate change

Rudolph focuses her research on reconstructing the past climate of Marion Island. 

She had the wonderful opportunity to visit the island for the past three years with study and project leaders, Profs Werner Nel from the University of Fort Hare and David Hedding from UNISA, she departed on a ship to Marion Island to conduct fieldwork.They published their research findings of fieldwork conducted in 2017 and 2018.  

According to Rudolph, research in Antarctica, the Southern Ocean, and islands such as Marion Island is very important. South Africa is the only African country with research stations that have the ability to explore these regions.

“Marion Island has many landforms that could only have been created by glacial erosional or depositional processes, with glaciers currently absent from the island. To determine when the island was last in a full glacial period, we date the formation ages of these landforms.”

“In the short time we have been visiting the island, it was impossible to notice any drastic changes in the island climate. That is why we use these very old landforms to tell us more about periods before humans visited the island,” she says. 

Rudolph believes that understanding the link between landscape responses and climate change of the past can help to better predict some of the climate change processes that are currently threatening the planet.

“There’s a principle in geography called ‘uniformitarianism’, whereby we assume that the earth-surface processes we observe today, are the same as those that have been active in the past,” says Rudolph.

As scientists, they thus look at evidence of past geomorphic processes (which remain in the landscape in various forms, e.g. residual landforms, stratigraphic sequences, etc.) to piece together what the past climate was like. In the same way, they also use this principle to predict how certain earth processes will change in the future, along with climate changes.

“In return, we understand how the climate and the earth’s surface interact, and we can better predict how the earth will respond to climate change,” Rudolph adds. 

Society to play its part in climate change

In the long run, we as the public should play our part in readying society for the effects of climate change. 

Rudolph says society can play a positive role in terms of climate change by educating themselves with unbiased, scientifically sound information on the true state of climate change and by responding within their own spheres of influence.

“Don’t leave everything up to politicians and policy. As the public, you can start to make progress by assessing the effects that climate change may have on your industry, business or society, and strategise on how to adapt your processes to deal with these changes.”

“Be responsible with our natural resources, reduce your waste, support local businesses that are sustainable, and volunteer at a local environmental protection/clean-up organisation. All the small efforts will eventually add up to substantial change,” she says. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept